Crossmark

Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization

Crossref DOI link: https://doi.org/10.1007/s10384-016-0434-4

Published Online: 2016-02-26

Published Print: 2016-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kachi, Ikuko

Yasukawa, Tsutomu

Kato, Aki

Takase, Noriaki

Morita, Hiroshi

Kubota, Ayae

Hirano, Yoshio

Uemura, Akiyoshi

Ogura, Yuichiro
Funding

Funding for this research was provided by:

The Research Committee on Chorioretinal Degenerations and Optic Atrophy, The Ministry of Health and Welfare of Japan

Grant-in Aid for Scientific Research (C) from the Japan Society for the Promotion of Science and a Grant-in Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan (25462758)
License Information

Text and Data Mining valid from 2016-02-26